Abstract

Tirzepatide is a novel dual-action peptide that activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. This unique mechanism offers potentially enhanced weight loss and glycemic control compared to selective GLP-1 agonists. Developed by Eli Lilly, tirzepatide is marketed as Mounjaro for type 2 diabetes and Zepbound for obesity.

Molecular Background

Key structural and pharmacological characteristics:

• Single peptide with balanced agonism at both GLP-1 and GIP receptors
• 39-amino acid peptide with fatty acid modification
• Extended half-life enabling once-weekly dosing
• First-in-class dual incretin agonist

Mechanism of Action

Tirzepatide’s dual mechanism provides complementary benefits:

GLP-1 Receptor Effects:

• Glucose-dependent insulin secretion enhancement
• Glucagon suppression
• Delayed gastric emptying
• Central appetite suppression

GIP Receptor Effects:

• Enhanced insulin sensitivity in adipose tissue
• Improved lipid metabolism
• Potential beta-cell protective effects
• Synergistic weight loss enhancement

Clinical Research Summary

Results from SURMOUNT and SURPASS clinical trial programs:

• Weight Loss: Up to 20-22% body weight reduction at highest doses
• HbA1c Reduction: Superior glycemic control vs. semaglutide in head-to-head trials
• Cardiovascular: Improvements in blood pressure, lipids, and inflammatory markers
• SURMOUNT-1: 91% of participants achieved at least 5% weight loss

Dosing Protocols

• Starting Dose: 2.5mg weekly for 4 weeks
• Maintenance Range: 5mg, 10mg, or 15mg weekly
• Maximum Dose: 15mg weekly
• Titration: Increase by 2.5mg every 4 weeks as tolerated

Comparison: Tirzepatide vs Semaglutide

Parameter	Tirzepatide	Semaglutide
Receptor Targets	GLP-1 + GIP (dual)	GLP-1 only
Avg. Weight Loss	15-22%	10-15%
HbA1c Reduction	2.0-2.3%	1.5-1.8%
Max Dose	15mg weekly	2.4mg weekly
Safety Data	Growing evidence	Extensive documentation

Safety Profile

Common adverse events similar to GLP-1 agonists:

• Gastrointestinal: Nausea, diarrhea, vomiting, constipation
• Injection Site: Local reactions (mild)
• Hypoglycemia: Rare when used alone, more common with insulin

Serious considerations:

• Thyroid C-cell tumor risk (rodent studies)
• Pancreatitis (rare)
• Gallbladder disease
• Acute kidney injury (dehydration-related)

Contraindications

• Personal or family history of medullary thyroid carcinoma
• Multiple endocrine neoplasia syndrome type 2
• Severe gastrointestinal disease
• Pregnancy and lactation

Current Research Status

Tirzepatide is FDA-approved as Mounjaro (diabetes) and Zepbound (obesity). Ongoing research investigates its effects on heart failure outcomes (SUMMIT trial), NASH/MASH, and obstructive sleep apnea. Head-to-head trials against semaglutide continue to refine clinical guidance.